Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials

In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals with CSPC Pharmaceutical and Sino Biopharmaceutical, Hengrui Pharma's Kal | AstraZeneca signed potential billion-dollar licensing deals with CSPC and Sino Biopharm, Hengrui's Kaleira-partnered oral GLP-1 candidate reported obesity and diabetes phase 3 data from China, and biotech insiders decried certain U.S. lawmakers' scrutiny over Chinese clinical trials as a distraction. And more.